{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:00:19Z","timestamp":1778641219949,"version":"3.51.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.intimp.2014.05.024","type":"journal-article","created":{"date-parts":[[2014,6,2]],"date-time":"2014-06-02T23:48:31Z","timestamp":1401752911000},"page":"439-446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Class I-specific histone deacetylase inhibitor MS-275 overrides TRAIL-resistance in melanoma cells by downregulating c-FLIP"],"prefix":"10.1016","volume":"21","author":[{"given":"Isabella","family":"Venza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Visalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosaria","family":"Oteri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Teti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Venza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2014.05.024_bb0005","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/archderm.139.8.1067","article-title":"Ocular melanoma: a review and the relationship to cutaneous melanoma","volume":"139","author":"Hurst","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.intimp.2014.05.024_bb0010","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3322\/canjclin.52.1.23","article-title":"Cancer statistics, 2002","volume":"52","author":"Jemal","year":"2002","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.intimp.2014.05.024_bb0015","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(02)08741-X","article-title":"Reliability of diagnosis of melanoma in situ","volume":"359","author":"Megahed","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2014.05.024_bb0020","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2001.19.16.3635","article-title":"Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma","volume":"19","author":"Balch","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.intimp.2014.05.024_bb0025","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1038\/sj.onc.1210134","article-title":"Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappa B but is related to downregulation of initiator caspases and DR4","volume":"26","author":"Kurbanov","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2014.05.024_bb0030","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.4049\/jimmunol.179.8.5441","article-title":"Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation","volume":"179","author":"Baritaki","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2014.05.024_bb0035","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/sj.cdd.4401416","article-title":"Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L\/TRAIL-induced apoptosis","volume":"11","author":"Chawla-Sarkar","year":"2004","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.intimp.2014.05.024_bb0040","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.bbrc.2013.10.114","article-title":"Impact of DNA methyltransferases on the epigenetic regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in malignant melanoma","volume":"441","author":"Venza","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.intimp.2014.05.024_bb0045","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.yexcr.2012.02.005","article-title":"Histone deacetylase (HDAC) inhibitors and regulation of TRAIL-induced apoptosis","volume":"318","author":"Fulda","year":"2012","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.intimp.2014.05.024_bb0050","first-page":"166","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs","volume":"3","author":"Kim","year":"2011","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.intimp.2014.05.024_bb0055","first-page":"55","article-title":"Epigenetic regulation of the TRAIL\/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance","volume":"2","author":"Jazirehi","year":"2013","journal-title":"Am J Clin Exp Immunol"},{"key":"10.1016\/j.intimp.2014.05.024_bb0060","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/pcmr.12049","article-title":"Class II-specific histone deacetylase inhibitors MC1568 and MC1575 suppress IL-8 expression in human melanoma cells","volume":"26","author":"Venza","year":"2013","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.intimp.2014.05.024_bb0065","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/jgm.1036","article-title":"Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines","volume":"9","author":"Lillehammer","year":"2007","journal-title":"J Gene Med"},{"key":"10.1016\/j.intimp.2014.05.024_bb0070","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.4161\/epi.22446","article-title":"PGE2 induces interleukin-8 derepression in human astrocytoma through coordinated DNA demethylation and histone hyperacetylation","volume":"7","author":"Venza","year":"2012","journal-title":"Epigenetics"},{"key":"10.1016\/j.intimp.2014.05.024_bb0075","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/sj.onc.1209122","article-title":"c-FLIP inhibits chemotherapy-induced colorectal cancer cell death","volume":"25","author":"Longley","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2014.05.024_bb0080","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1038\/sj.onc.1208585","article-title":"HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma","volume":"24","author":"Singh","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2014.05.024_bb0085","first-page":"1125","article-title":"Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways","volume":"16","author":"Shankar","year":"2005","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.intimp.2014.05.024_bb0090","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1593\/neo.04655","article-title":"Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma","volume":"7","author":"Fandy","year":"2005","journal-title":"Neoplasia"},{"key":"10.1016\/j.intimp.2014.05.024_bb0095","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.21054","article-title":"HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL","volume":"43","author":"Pathil","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.intimp.2014.05.024_bb0100","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1002\/jcb.24090","article-title":"HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins","volume":"113","author":"Jung","year":"2012","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.intimp.2014.05.024_bb0105","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1158\/0008-5472.CAN-06-4397","article-title":"Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity","volume":"67","author":"Harms","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.intimp.2014.05.024_bb0110","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1007\/s10495-006-0283-6","article-title":"Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells","volume":"11","author":"Gillespie","year":"2006","journal-title":"Apoptosis"},{"key":"10.1016\/j.intimp.2014.05.024_bb0115","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0006-2952(03)00509-4","article-title":"The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis","volume":"66","author":"Zhang","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.intimp.2014.05.024_bb0120","doi-asserted-by":"crossref","first-page":"e951","DOI":"10.1038\/cddis.2013.481","article-title":"Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer","volume":"4","author":"Riley","year":"2013","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.intimp.2014.05.024_bb0125","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1046\/j.0022-202x.2001.01418.x","article-title":"Selective expression of FLIP in malignant melanocytic skin lesions","volume":"117","author":"Bullani","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.intimp.2014.05.024_bb0130","first-page":"2747","article-title":"Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma","volume":"59","author":"Zhang","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.intimp.2014.05.024_bb0135","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1038\/sj.onc.1210985","article-title":"Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis","volume":"27","author":"Geserick","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2014.05.024_bb0140","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.0022-202X.2004.23420.x","article-title":"Resistance of human melanoma cells against the death ligand TRAIL is reversed by ultraviolet-B radiation via downregulation of FLIP","volume":"123","author":"Zeise","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.intimp.2014.05.024_bb0145","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/40657","article-title":"Inhibition of death receptor signals by cellular FLIP","volume":"388","author":"Irmler","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2014.05.024_bb0150","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/cdd.2012.8","article-title":"Identification of an acetylation-dependant Ku70\/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis","volume":"19","author":"Kerr","year":"2012","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.intimp.2014.05.024_bb0155","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.ejca.2011.11.009","article-title":"Vorinostat\/SAHA-induced apoptosis in malignant mesothelioma is FLIP\/caspase 8-dependent and HR23B-independent","volume":"48","author":"Hurwitz","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.intimp.2014.05.024_bb0160","first-page":"227","article-title":"Histone deacetylase inhibition by valproic acid down-regulates c-FLIP\/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy","volume":"15","author":"Schuchmann","year":"2006","journal-title":"Oncol Rep"},{"key":"10.1016\/j.intimp.2014.05.024_bb0170","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/bjh.12108","article-title":"Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia","volume":"160","author":"McLornan","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.intimp.2014.05.024_bb0175","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1091\/mbc.E12-10-0737","article-title":"Cells surviving fractional killing by TRAIL exhibit transient but sustainable resistance and inflammatory phenotypes","volume":"24","author":"Flusberg","year":"2013","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.intimp.2014.05.024_bb0180","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2174\/1568009611313040005","article-title":"The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases","volume":"13","author":"Rao-Bindal","year":"2013","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.intimp.2014.05.024_bb0185","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/bjc.2011.527","article-title":"Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours","volume":"106","author":"Pili","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.intimp.2014.05.024_bb0190","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1517\/13543784.2011.613822","article-title":"Entinostat for treatment of solid tumors and hematologic malignancies","volume":"20","author":"Knipstein","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.intimp.2014.05.024_bb0195","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1158\/1078-0432.CCR-07-1461","article-title":"A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas","volume":"14","author":"Gore","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.intimp.2014.05.024_bb0200","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00401-006-0082-8","article-title":"Ex vivo therapy of malignant melanomas transplanted into organotypic brain slice cultures using inhibitors of histone deacetylases","volume":"112","author":"H\u00f6lsken","year":"2006","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.intimp.2014.05.024_bb0205","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1074-5521(02)00092-3","article-title":"Deacetylase enzymes: biological functions and the use of small-molecule inhibitors","volume":"9","author":"Grozinger","year":"2002","journal-title":"Chem Biol"},{"key":"10.1016\/j.intimp.2014.05.024_bb0210","doi-asserted-by":"crossref","first-page":"487","DOI":"10.4161\/epi.4.7.9883","article-title":"Dnmt3\/transcription factor interactions as crucial players in targeted DNA methylation","volume":"4","author":"Hervouet","year":"2009","journal-title":"Epigenetics"},{"key":"10.1016\/j.intimp.2014.05.024_bb0215","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/77124","article-title":"DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters","volume":"25","author":"Robertson","year":"2000","journal-title":"Nat Genet"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576914002045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576914002045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T17:59:05Z","timestamp":1538589545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576914002045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S1567576914002045"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2014.05.024","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Class I-specific histone deacetylase inhibitor MS-275 overrides TRAIL-resistance in melanoma cells by downregulating c-FLIP","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2014.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}